Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27339213 | 0.91 | DRD2 (0.42) | DRD2 | |
| SCHEMBL14685577 | 0.86 | DRD2 (0.44) | DRD2 | |
| SCHEMBL12445058 | 0.86 | DRD2 (0.44) | DRD2 | |
| SCHEMBL14380838 | 0.86 | GNAO1 (0.52) | GNAO1GNAI3GNAI1EPHX1EPHX2 | |
| SCHEMBL23828683 | 0.85 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SLC6A4KCNH2 | |
| SCHEMBL31273842 | 0.85 | DRD2 (0.47) | DRD2GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL24753348 | 0.84 | GNAO1 (0.60) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL7741719 | 0.83 | GNAO1 (0.49) | DRD2GNAO1GNAI3GNAI1EPHX1 | |
| SCHEMBL7741626 | 0.82 | GNAO1 (0.63) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL27398041 | 0.82 | GNAO1 (0.63) | GNAO1GNAI3GNAI1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023016567-A1 | METHODS OF TREATING A DISEASE OR DISORDER | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-08 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | DRD2 4254/4885GNAO1 4474/4885GNAI3 3452/4885 |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | RYR1, RYR2, ATP2A1 | DRD2 2935/4885GNAO1 734/4885GNAI3 708/4885 |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | DRD2 3477/4885GNAO1 1994/4885GNAI3 3718/4885 |
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | DRD2 4299/4885GNAO1 2597/4885GNAI3 575/4885 |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | DRD2 2926/4885GNAO1 1858/4885GNAI3 1885/4885 |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | DRD2 434/4885GNAO1 1056/4885GNAI3 1845/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | DRD2 2709/4885GNAO1 236/4885GNAI3 472/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | DRD2 2161/4885GNAO1 434/4885GNAI3 785/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885GNAO1 2977/4885GNAI3 1664/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | DRD2 2470/4885GNAO1 787/4885GNAI3 1189/4885 |
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | CRBN, CUL3, UBE3A | DRD2 1057/4885GNAO1 2575/4885GNAI3 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.